Loading...

REGN REGENERON PHARMACEUTICALS INC Earnings Reports 8-K Filing

RGNR

RGN

REGENERON PHARMACEUTICALS INC

(REGN)

2024 8-K

Show Summary

Summary

Financial Statements

Financial Results

Financial Update

Q3 Earnings Report

Q3 2024 Preview

Earnings Reports

Financial Results

Shareholder Vote Results

Financial Results

Financial Results Announcement

Management Appointments

Corporate Update at Healthc...

Financial Results Announcement

Financial Results

Earnings Reports

Amendment to Bylaws and Sha...

Financial Results Announcement

Management Changes

Financial Results for Q1 2023

External Links:

Regeneron Pharmaceuticals expects a $56 million charge for in-process research and development in Q3 2024, impacting net income per share by about $0.43, with results still subject to finalization.

AI Assistant

REGENERON PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.